Phase I trial of radiolabeled antibody as an adjuvant to radiation therapy for unresectable non-small cell bronchogenic carcinoma: A Radiation Therapy Oncology Group study

D. J. Moylan, S. E. Order, E. Zinreich

Research output: Contribution to journalArticle

Abstract

A phase I trial was conducted by the Radiation Therapy Oncology Group to determine the toxic effects of polyclonal iodine-131-labeled antiferritin and anti-CEA as a potential adjuvant to external beam radiotherapy for unresectable non-small cell brochogenic carcinoma (protocol 81-03). A total of 51 patients have been registered for this study; 32 received at least one cycle of radiolabeled anti-CEA or antiferritin. Most patients received external beam irradiation according to a split-course technique using 300-cGy fractions for a total dose of 5100-5400 cGy over 6 1/2 weeks. In three patients, other fractionation schemes were employed. If there was no evidence of metastatic disease during a 3-week rest period following the completion of external beam radiation therapy, the patients received radiolabeled antibody, either antiferritin or anti-CEA (20 mCi on Day 0 and 10 mCi on Day 5). Injections of these polyclonally derived antibodies were then repeated cyclicly by altering the species of derivation (rabbit, pig, or monkey) every 2 months for three or four cycles, as long as there was no evidence of metastatic disease or toxic effects. Toxic effects have been acceptable and have been limited to radiation pneumonitis in eight antibody-treated patients and moderate myelosuppression in six. There were no fatalities related to radiolabeled antibody administration. Currently, four patients are alive without disease at 9-18 months, and another 13 are alive with evidence of disease at 3-20 months. The ability of these antibodies to target tumor deposits of non-small cell lung carcinoma has been demonstrated by single-photon emission computed tomography and γ-camera scanning of resected specimens from patients who have received tracer doses of radiolabeled antiferritin prior to surgery. Further investigation of the role of radiolabeled antibodies in the management of non-small cell bronchogenic carcinoma is also received.

Original languageEnglish (US)
Pages (from-to)109-113
Number of pages5
JournalCancer Treatment Symposia
VolumeVOL. 2
StatePublished - Jan 1 1985
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Phase I trial of radiolabeled antibody as an adjuvant to radiation therapy for unresectable non-small cell bronchogenic carcinoma: A Radiation Therapy Oncology Group study'. Together they form a unique fingerprint.

  • Cite this